Sanofi’s $1.53 Billion China Bet Signals a New Map for Biotech Innovation
The rovadicitinib deal is about more than one blood-cancer and
Chai Discovery’s $130m bet: can “CAD for molecules” make biologics faster and cheaper?
With a $130m Series B, the startup is betting that
Dermatology’s next play: bispecifics that shut down OX40L and TNF
Pairing a T-cell co-stimulatory brake with an inflammatory workhorse is
A Champion Departs: Peter Marks’ Resignation and Biotech’s Crossroads
When Dr. Peter Marks walked out of the FDA’s headquarters
From Collapse to Comeback: Inside Biotech’s ‘Death-to-Rebirth’ Cycle
Layoffs Hit Biotech Hubs Hard In labs from Boston’s Kendall
AbbVie Enters Obesity Drug Market with $2.2B Gubra Licensing Deal
AbbVie, a leading biopharmaceutical company, has taken a significant step
Draupnir Bio Raises €12 Million to Advance Oral Protein Degraders Targeting Extracellular Proteins
Draupnir Bio, a cutting-edge biotechnology company, has successfully raised €12
AI-Powered Drug Repurposing by BioXcel Therapeutics Accelerates Development of New Neuropsychiatric Treatments
1. Introduction BioXcel Therapeutics is a biopharmaceutical company leveraging artificial
MOST POPULAR
